Novartis India Stake Sale: Consortium to Buy 70.68% for ₹1,446 Crore

Novartis AG Announces Exit from Indian Unit

Swiss pharmaceutical major Novartis AG has announced its decision to sell its entire 70.68% stake in its publicly listed Indian subsidiary, Novartis India Limited. The stake, comprising 17.4 million equity shares, will be acquired by a consortium led by private equity firm ChrysCapital. The transaction, valued at approximately ₹1,446 crore, marks a significant shift in ownership for the Indian entity and aligns with the parent company's global restructuring strategy.

The consortium of buyers includes WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners. This acquisition has triggered a mandatory open offer for the public shareholders of Novartis India, as required by the Securities and Exchange Board of India (SEBI) regulations.

The Acquisition Agreement

The share purchase agreement was executed on February 19, 2026. Under the terms, the consortium will acquire the controlling stake from Novartis AG. This move is a result of a strategic review initiated by Novartis in February 2024, aimed at transforming the global parent into a 'pure-play innovative medicines company'. The company stated that this divestment helps adapt its footprint for efficient and sustainable long-term growth, consistent with its global strategy. The transaction is subject to the fulfillment of certain conditions and is expected to close in the third quarter of 2026.

Details of the Mandatory Open Offer

Following the acquisition agreement, the consortium has launched a mandatory open offer to acquire an additional 26% of the voting share capital from the public shareholders of Novartis India. This offer allows the consortium to purchase up to 6,419,608 equity shares.

The open offer price has been fixed at ₹860.64 per share, representing a 3.64% premium over the stock's closing price of ₹830.45 on the preceding trading day. The total consideration for the open offer, assuming full acceptance, will amount to approximately ₹552.5 crore, payable entirely in cash. The tendering period for shareholders is scheduled from April 21 to May 5, 2026.

Post-Transaction Ownership and Changes

The new ownership structure will depend on the response to the open offer. If the offer is fully subscribed, the consortium's combined shareholding in Novartis India will increase to 96.68%. In the event that no shares are tendered, their stake will remain at the 70.68% acquired from Novartis AG.

As part of the agreement, Novartis India will undergo a significant rebranding. The company has committed to changing its name to remove all references to the 'Novartis' brand within 120 days of the transaction's completion. Following the deal, Novartis AG will no longer be a promoter and will be reclassified under the public shareholder category as per SEBI regulations.

Market Reaction and Stock Performance

The announcement of the stake sale was met with a strong positive reaction from the market. Shares of Novartis India surged by as much as 20% on February 20, 2026, hitting the upper trading circuit. The stock price climbed significantly, reflecting investor optimism about the change in control and the premium offered to public shareholders.

Strategic Implications

For Novartis AG, this sale is a key step in its global strategy to focus on innovative medicines by divesting non-core assets. The move comes at a time when the Indian unit has reportedly seen a decline in sales, suggesting a strategic realignment was necessary. For Novartis India, the entry of a private equity-led consortium signals a new chapter. The new ownership may bring a fresh strategic direction, operational efficiencies, and a renewed focus on growth in the Indian pharmaceutical market.

Conclusion

The sale of Novartis AG's stake in its Indian arm to a ChrysCapital-led consortium is a landmark deal in the Indian pharmaceutical sector. It provides an exit for the Swiss parent in line with its global strategy and introduces new ownership with a potential for strategic transformation at Novartis India. The mandatory open offer provides public shareholders with an opportunity to exit at a premium, while the market awaits the new strategic direction the company will take under its new leadership.